|1.||Pawlikowski, Marek: 6 articles (09/2011 - 02/2003)|
|2.||Pisarek, Hanna: 5 articles (09/2011 - 01/2009)|
|3.||Culler, Michael D: 5 articles (11/2009 - 06/2003)|
|4.||Culler, M D: 5 articles (03/2004 - 02/2000)|
|5.||Kumar, Ujendra: 4 articles (03/2009 - 07/2005)|
|6.||Lupp, Amelie: 3 articles (09/2015 - 08/2011)|
|7.||Schulz, Stefan: 3 articles (09/2015 - 08/2011)|
|8.||Kubiak, Robert: 3 articles (09/2011 - 01/2009)|
|9.||Winczyk, Katarzyna: 3 articles (09/2011 - 01/2010)|
|10.||Kunert-Radek, Jolanta: 3 articles (01/2011 - 07/2009)|
01/01/2011 - "Elevated SSTR1, SSTR2, and DR2 tumor expression may help improve responsiveness to SA and DA therapy; however, this study may not have been appropriately powered to observe significant effects in the clinical response. "
09/29/2015 - "Additionally, SSTR1 expression was higher in G3a than in G3b tumors. "
05/01/2013 - "Quantitative PCR analysis showed expression of SSTR1 and SSTR2 in the majority of tumors, while SSTR3-5 were expressed at low levels. "
06/28/2012 - "We investigated the expression of SSTR subtypes (SSTR-1, 2A, 3, 4 and 5) using real-time reverse transcription polymerase chain reaction (RT-PCR) method and immunohistochemistry in 32 neuroendocrine neoplasms (9 NET G1, 2 NET G2, 18 NECs G3 and 3 mixed NEC G3) of various primary sites. "
09/01/2011 - "In non-functioning tumors, compatibility between IHC and PCR results was observed for SSTR 1 and 2 in 62.5% of the samples. "
09/01/1999 - "The SSTR1 transcript was also highly expressed in prolactinomas (1296 +/- 669 pg/pg GAPDH). "
07/01/2009 - "The pattern of SSTR immunostaining (estimated according to the percentage frequency of appearance) was in acromegaly: SSTR 5 > SSTR 1 > SSTR 2A = SSTR 3 > SSTR 2B, in prolactinomas: SSTR 2B = SSTR 3 = SSTR 5 > SSTR 1 = SSTR 2A, in gonadotropinomas: SSTR 3 > SSTR 2B > SSTR 1 = SSTR 2A > SSTR 5, in corticotropinomas: SSTR 2A > SSTR 1 = SSTR 3 > SSTR 5 > SSTR 2B. "
05/01/2008 - "Prolactinomas express somatostatin (SST) receptor subtypes, SSTR1, 2, and 5. The aim of this study was to determine whether different SST compounds could overcome the resistance to DA in prolactinomas. "
05/01/2008 - "The SSTR1 agonist, BIM-23926, did not suppress PRL in prolactinomas. "
09/01/1999 - "In conclusion, prolactinomas have a specific pattern of SSTR subtype mRNA expression (SSTR5 and SSTR1). "
|3.||Neuroendocrine Tumors (Neuroendocrine Tumor)
01/01/2010 - "The summarized expression pattern of SSTR in the investigated neuroendocrine tumors in our material was: SSTR 1> SSTR 5> SSTR 3> SSTR 2A> SSTR 2B. "
06/28/2012 - "Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry."
01/01/2010 - "SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors."
05/01/2012 - "Somatostatin analogues, which are used to treat neuroendocrine tumors, target the high levels of somatostatin receptor subtype 2 (SSTR1; alias sst2) expressed in these cancers. "
01/01/2010 - "The aim of study was to assess the presence of all the 5 subtypes of SSTR 1-5 (including 2A and 2B SSTR isoforms) in surgically treated human neuroendocrine tumors (NETs) to establish which receptor subtype is the dominant form of somatostatin receptor in particular tumor and thus to be able to predict which somatostatin analog will be effective in NETs treatment. "
01/01/2015 - "Among histological adenoma types, SSTR1 was significantly higher in null-cell adenomas and SSTR3 was lower in silent corticotroph adenomas. "
01/01/2009 - "Results of SSTR 1-5 detection in other thyroid pathologies like follicular adenomas and papillary cancers are still scarce and often controversial, depending of investigation method used. "
01/01/2006 - "The development of specific somatostatin subtypes analogs, mainly for SSTR5, of a SSTR2-SSTR5 bispecific compound, and of a "universal" analog with high affinity to SSTR1, 2, 3, and 5 showed preliminary, albeit promising results for the treatment of resistant somatotropic adenomas."
06/01/2007 - "In comparison to the normal pituitary, sstr2A>sstr1>sstr5>sstr3 mRNAs were expressed in the TSH-secreting adenomas examined. "
07/01/2003 - "SSTR2 mRNA was identified in 77% of the adenomas, SSTR1 and SSTR3 in 69% and SSTR5 in 60%. "
09/01/2004 - "Histological analysis demonstrated significant islet hyperplasia in the SSTR 1/5 -/- mouse pancreas. "
01/01/2009 - "SSTR 1 is the dominant form in the thyroid gland tumor and hyperplasia. "
09/01/2004 - "Double-gene ablation of SSTR1 and SSTR5 in mice resulted in a distinct phenotype with islet cell hyperplasia, hyperinsulinemia, and improved glucose tolerance. "
|1.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|2.||Somatostatin Receptors (Somatostatin Receptor)
|3.||Protein Isoforms (Isoforms)
|9.||Messenger RNA (mRNA)
|10.||somatostatin receptor type 1
|1.||Prostatectomy (Retropubic Prostatectomy)
|2.||Heterologous Transplantation (Xenotransplantation)